

**Fortis Healthcare Limited**

Tower A, Unitech Business Park, Block - F,
South City 1, Sector - 41, Gurgaon,
Haryana - 122001 (India)

Tel : 0124 492 1033

Fax : 0124 492 1041

Emergency 105010

E-mail : contactus@fortishealthcare.com

Website : www.fortishealthcare.com

FHL/SEC/STEX/RR/2013-14

August 08, 2013

**The National Stock Exchange of India Ltd.
Corporate Communications Department
"Exchange Plaza", 5th Floor,
Bandra-Kurla Complex, Bandra (East),
Mumbai - 400051
Scrip Symbol: FORTIS**

**BSE Limited
Corporate Services Department
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001**

Scrip Code:532843

Sub: Outcome of the Board Meeting

Dear Sirs,

This is to inform you that the Board of Directors of the Company has, at its Meeting held today, i.e., August 08, 2013, approved the following:

- a) 'Un-audited Financial Results' of the Company and 'Limited Review Report' thereon for the Quarter ended June 30, 2013;
- b) Closure of Register of Members and Share Transfer Books of the Company from Monday, September 23, 2013 to Friday, September 27, 2013 (both days inclusive);
- c) Convening of 17th Annual General Meeting of the Company on Friday, September 27, 2013 at 11.30 A.M. at PHD Chamber of Commerce and Industry, PHD House, 4/2, Siri Institutional Area, August Kranti Marg, New Delhi-110016; and

Please find attached the 'Un-audited Consolidated and Standalone Financial Results' of the Company and 'Limited Review Report' thereon for the Quarter ended June 30, 2013 alongwith a copy of the press release to be issued in this regard.

This is for your information and records please.

Thanking you,

Yours faithfully,
For Fortis Healthcare Limited


**Rahul Ranjan
Company Secretary**

Encl: As above

FORTIS HEALTHCARE LIMITED

Regd. Office: Escorts Heart Institute and Research Centre, Okhla Road, New Delhi - 110 025 (India)
Tel: +91-11-2682 5000, Fax: +91-11-4162 8435

Limited Review Report

**Review Report to
The Board of Directors
Fortis Healthcare Limited**

1. We have reviewed the accompanying statement of unaudited financial results of Fortis Healthcare Limited ('the Company') for the quarter ended June 30, 2013 (the "Statement"), except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been reviewed by us. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. We draw attention to non-provision of proportionate premium on redemption of US Dollar 100,000,000 5% Foreign Currency Convertible Bonds due 2015 amounting to Rs. 1,175.90 lacs. Management has represented that the redemption premium will be offset against the securities premium account and accordingly, no adjustments have been considered in the results. Our conclusion is not qualified in respect of this matter.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting", notified pursuant to the Companies (Accounting Standards) Rules, 2006, (as amended) and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.R. BATLIBOI & CO. LLP
ICAI Firm registration number: 301007E
Chartered Accountants,



per Pankaj Chadha
Partner
Membership No.: 91813
Place: Gurgaon
Date: 8/8/13

**Certified True Copy
For Fortis Healthcare Limited**

Company Secretary

Limited Review Report

**Review Report to
The Board of Directors
Fortis Healthcare Limited**

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Fortis Group comprising Fortis Healthcare Limited ('the Company'), its subsidiaries, joint ventures and associates (together, 'the Fortis Group'), for the quarter ended June 30, 2013 (the "Statement"), being submitted by the Company pursuant to the requirement of Clause 41 of the Listing Agreement, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been reviewed by us. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. a) We did not review the financial results of certain overseas subsidiaries whose financial results prepared under International Financial Reporting Standards ('IFRS') or Singapore Financial Reporting Standards ('SFRS'), in the aggregate, reflect total assets and revenues of Rs. 332,446.94 lacs and Rs. 70,650.34 lacs respectively. We also did not review the financial results of an overseas associate whose financial results, prepared under IFRS, in the aggregate reflect net loss of Rs. 17.68 lacs. The financial results of these subsidiaries and associates have been prepared in accordance with IFRS or SFRS and have been reviewed by other auditors who have submitted their review conclusions, prepared under generally accepted auditing standards of their respective countries, to the management of the respective companies, copies of which have been provided to us by the Company. Our conclusion thus, insofar it relates to amounts included in respect of these subsidiaries and associates, is based solely on the reports of the other auditors under the accounting policies generally accepted in respective countries and our review of the conversion process followed by management on a test basis. Further we did not review the financial results of an overseas associate whose financial results, prepared under IFRS, in the aggregate reflect net profit of Rs. 90.50 lacs. These financial results and other financial information have been prepared by the management, and our conclusion is based solely on the management certified accounts. The management of the Company has converted these reviewed financial results of the Company's subsidiaries and associates to accounting principles generally accepted in India, for the purpose of preparation of the Company's consolidated financial results under accounting principles generally accepted in India.
- b) We did not review the financial results of certain subsidiaries, whose financial results prepared under the generally accepted accounting principles accepted in India, reflect total assets of Rs. 459,803.10 lacs as at June 30, 2013 and total revenue of Rs. 88,327.62 lacs for the quarter then ended. These financial results and other financial information have been reviewed by other auditors whose reports have been furnished to us, and our conclusion is based solely on the report of other auditors. We also did not review the financial results of certain subsidiaries, whose financial results prepared under the generally accepted accounting principles accepted in India, reflect total assets of Rs. 902.25 lacs as at June 30, 2013 and total revenue of Rs. 241.33 lacs for the quarter then ended. These financial results and other financial information have been prepared by the management, and our conclusion is based solely on the management certified accounts.



S.R. BATLIBOI & CO. LLP

Chartered Accountants

- c) We did not review the financial results of certain joint ventures, whose financial results reflect total assets of Rs.1,903.56 lacs as at June 30, 2013 and total revenue of Rs. 820.41 lacs for the quarter then ended, being the proportionate share of Fortis Group, for the quarter then ended. These financial results and other financial information have been reviewed by other auditors whose reports have been furnished to us, and our conclusion is based solely on the report of other auditors. We also did not review the financial results of certain joint ventures, whose financial results reflect total assets of Rs. 693.47 lacs as at June 30, 2013 and total revenue of Rs. 131.24 lacs for the quarter then ended, being the proportionate share of Fortis Group, for the quarter then ended. These financial results and other financial information have been prepared by the management, and our conclusion is based solely on the management certified accounts.
- d) We did not review the financial results of an associate, whose financial results reflect net loss of Rs. 17.68 lacs, being the proportionate share of Fortis Group, for the quarter ended June 30, 2013. These financial results and other financial information have been reviewed by other auditors whose reports have been furnished to us, and our conclusion is based solely on the report of other auditors. We also did not review the financial results of an associate, whose financial results reflect net profit of Rs. 90.50 lacs, being the proportionate share of Fortis Group, for the quarter ended June 30, 2013. These financial results and other financial information have been prepared by the management, and our conclusion is based solely on the management certified accounts.
4. We draw attention to non-provision of proportionate premium on redemption of US Dollar 100,000,000 5% Foreign Currency Convertible Bonds due 2015 amounting to Rs. 1,175.90 lacs. Management has represented that the redemption premium will be offset against the securities premium account and accordingly, no adjustments have been considered in the results. Our conclusion is not qualified in respect of this matter.
5. (a) We draw attention to Note 6 to the financial results which describe the material uncertainty related to the outcome of certain tax demands against the Company aggregating Rs. 8,922.50 (after adjusting Rs. 14,046.56 lacs for which the subsidiary company has a legal right to claim from erstwhile promoters), related to the amalgamation of EHIRC, Delhi Society with EHIRC, Chandigarh Society and thereafter registration of EHIRC, Chandigarh Society as the Company. Our conclusion is not qualified in respect of this matter.
- (b) We draw attention to Note 6 to the financial results which describe the material uncertainty related to the outcome of the lawsuit filed by the Company against Delhi Development Authority (DDA) for termination of certain land leases allotted by DDA and consequent eviction notices issued to the Company by the Estate Officer of DDA. Our conclusion is not qualified in respect of this matter.
6. Based on our review conducted as above and on consideration of reports of other auditors on the unaudited separate quarterly financial results and on the other financial information of the components, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited consolidated financial results prepared in accordance with recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting", notified pursuant to the Companies (Accounting Standards) Rules, 2006, (as amended) and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.R. BATLIBOI & CO. LLP

ICAI Firm registration number: 301003E

Chartered Accountants

per Pankaj Chadha
Partner
Membership No.: 91813
Place: Gurgaon
Date: 8/12/13




Certified True Copy
For Fortis Healthcare Limited

Company Secretary

FORTIS HEALTHCARE LIMITED
STATEMENT OF UNAUDITED RESULTS FOR THE QUARTER ENDED JUNE 30, 2013

Particulars	Consolidated				Standalone			
	Quarter ended		Year ended		Quarter ended		Year ended	
	30-Jun-13 (Unaudited)	31-Mar-13 (Audited) (Refer note 2)	30-Jun-12 (Unaudited)	31-Mar-13 (Audited)	30-Jun-13 (Unaudited)	31-Mar-13 (Audited) (Refer note 2)	30-Jun-12 (Unaudited)	31-Mar-13 (Audited)
1. Income from operations	150,363	159,479	139,558	599,068	9,428	8,758	8,089	33,447
2. Other operating income	1,377	1,551	1,371	6,096	387	451	401	1,850
3. Total income	151,740	161,030	140,929	605,164	9,815	9,209	8,490	35,297
4. Expenditure								
(a) Cost of material consumed	28,547	27,686	25,620	106,587	3,091	2,519	2,602	10,156
(b) Employees benefit expenses	49,195	53,558	47,207	199,274	3,272	2,587	2,313	10,111
(c) Other expenditure	68,398	68,490	49,905	231,431	4,545	3,801	3,351	15,166
Total	146,138	149,734	122,732	537,292	10,908	8,907	8,266	35,413
5. Profit (+) Loss (-) from operations before other income, finance cost, depreciation and amortisation (3-4)	5,602	11,296	18,197	67,872	(1,093)	302	224	(116)
6. Other income	4,262	3,693	3,637	15,696	4,658	3,765	5,252	19,057
7. Exceptional gain/ (loss) (refer note 7)	(8,459)	(23)	(209)	96,459	-	-	-	-
8. Profit from operations before finance cost, depreciation and amortisation (5+6-7) (EBITDA)	1,405	14,966	21,625	180,027	3,565	4,067	5,476	18,941
9. Net depreciation/ impairment & amortization expenses	6,951	10,760	5,653	37,059	449	1,156	371	2,347
10. Profit from operations before finance costs (8-9)	(5,546)	4,206	14,962	142,968	3,116	2,931	5,105	16,594
11. Finance costs	14,811	12,770	17,833	63,400	2,217	3,658	3,296	13,386
12. Profit/ (loss) from operations before tax (10-11) (including profit attributable to discontinuing operations, refer note 8)	(20,357)	(8,564)	(2,871)	79,568	899	(727)	1,809	3,208
13. Tax expense	1,583	2,175	1,966	23,132	145	178	476	1,483
14. Net profit/ (loss) from ordinary activities after tax (12-13)	(21,940)	(10,739)	(4,837)	56,436	754	(905)	1,333	1,725
15. Less : Minority interest in profit	283	1,141	1,343	7,267	-	-	-	-
16. Add : Share in profit of associate companies	93	258	138	824	-	-	-	-
17. Net profit/(loss) after taxes, minority interest and share of profit/(loss) of associates (14-15+16)	(22,130)	(11,622)	(6,042)	49,993	754	(905)	1,333	1,725
18. Paid-up equity share capital (Face Value ₹10 per Share)	45,904	40,521	40,518	40,521	45,904	40,521	40,518	40,521
19. Reserves excluding revaluation reserves				330,134				279,552



MF

20. Earnings per share (excluding exceptional items)	(3.20)	(2.86)	(1.44)	(11.47)	0.18	(0.22)	0.33	0.43
- Basic	(3.20)	(2.86)	(1.44)	(11.47)	0.18	(0.22)	0.33	0.43
- Diluted								
Part II								
A. Particulars of Shareholding								
1. Public shareholding - No of shares	128,885,017	75,053,386	75,025,766	75,053,386	128,885,017	75,053,386	75,025,766	75,053,386
- Percentage of shareholding	28.08%	18.52%	18.50%	18.52%	28.08%	18.52%	18.50%	18.52%
2. Promoters and promoter group shareholding								
a) Pledged/ encumbered - No of shares	222,596,300	210,533,822	254,322,700	210,533,822	222,596,300	210,533,822	254,322,700	210,533,822
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	67.42%	63.77%	77.00%	63.77%	67.42%	63.77%	77.00%	63.77%
- Percentage of shares (as a % of the total share capital of the company)	48.45%	51.96%	62.80%	51.96%	48.45%	51.96%	62.80%	51.96%
b) Non-encumbered - No of shares	107,557,648	119,620,127	75,831,249	119,620,127	107,557,648	119,620,127	75,831,249	119,620,127
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	32.58%	36.23%	23.00%	36.23%	32.58%	36.23%	23.00%	36.23%
- Percentage of shares (as a % of the total share capital of the company)	23.43%	29.52%	18.70%	29.52%	23.43%	29.52%	18.70%	29.52%
B. Investor complaints								
Pending at the beginning of the quarter	Nil							
Received during the quarter	1							
Disposed off during the quarter	1							
Remaining unsolved at the end of the quarter	Nil							

Notes to the results:

1. The above unaudited financial results for the quarter ended June 30, 2013 have been reviewed by the Audit, Risk & Control Committee and approved by the Board of Directors at their respective meetings held on August 07, 2013 and August 08, 2013. These unaudited financial results for the quarter ended June 30, 2013 were subjected to a limited review by the auditors of the Company.
2. The figures for the quarter ended March 31, 2013 are the balancing figures between audited figures in respect of the full financial year upto March 31, 2013 and the unaudited published year to date figures upto December 31, 2012 being the end of the third quarter of the financial year 2012-2013, which was subjected to a limited review.



3. Segment Reporting

Business segments:

The Group is primarily engaged in the business of healthcare services, which in the opinion of management is considered to be the only reportable business segment as per Accounting Standard 17 on 'Segment Reporting' notified under the Companies (Accounting Standards) Rules, 2006 as amended. Healthcare services include various patient care services delivered through clinical establishment, medical services companies, pathology and radiology services, etc.

Geographical segments:

The group operates in the business segment explained above in two principal geographical areas, geographical segments being classified as secondary segment. In India, its home country, the group focuses largely on healthcare services. Additionally, the group's operations 'Outside India' are now mostly focusing on South East Asia and Middle East through the group's headquarters based in Singapore. The group primarily operates in following countries: Singapore, Hong Kong, Vietnam and Mauritius. During the current quarter, the transaction for disposal of the Group's interest in Dental Corporation Holdings Limited ("DC"), Australia was concluded.

Revenue from operations –by geographical markets

The following table shows the distribution of the Company's consolidated revenues by geographical market.

(₹ In lacs)

Region	Quarter ended			Year ended
	June 30, 2013	March 31, 2013	June 30, 2012	March 31, 2013
Outside India*	70,553	85,038	74,008	317,984
India	81,187	75,992	66,921	287,180
Total	151,740	161,030	140,929	605,164

* Includes revenue relating to discontinuing operations (see note 8 below).

4. Other income includes interest income, foreign exchange fluctuation gain, profit on sale of assets, profit on sale of investments, forward cover premium amortization and miscellaneous income, whichever is relevant for the period.

5. Due to restatement and settlement of foreign currency monetary items, the Company and its subsidiaries recognize foreign exchange fluctuation differences in the profit and loss account. This difference may result in either net gain or loss and is accordingly, included under 'other income' or 'other expenditure' for the specific period. Further exchange difference arising from foreign currency borrowings to the extent that they are regarded as adjustment to the interest costs have been reported under finance cost.

and



6. In case of one of the subsidiary, that was formed after amalgamation of EHIRC, Delhi Society with EHIRC, Chandigarh Society and thereafter registration of EHIRC, Chandigarh Society as a company.

a) Delhi Development Authority ('DDA') had terminated the lease deeds and allotment letters relating to land parcels on which hospital of one of the subsidiary company exists. Consequent to termination DDA issued show cause notice and initiated eviction proceedings against the subsidiary company. Both these matters are currently pending in various courts of law. Based on experts' opinions, management is confident that subsidiary company will be able to suitably defend the termination order and eviction proceedings and accordingly considers that no adjustments are required to the financial result.

b) Further, the subsidiary company also has open tax demands of ₹ 8,923 lacs (after adjusting ₹ 4,461 lacs for which the Company has a legal right to claim from erstwhile promoters and ₹ 9,585 lacs which has been adjusted by the revenue authorities out of an escrow account which was maintained out of sale consideration payable by the Company to the erstwhile promoters) for relevant assessment years. Based on the experts' opinions, management considers these tax demands as not tenable against the subsidiary company and management is confident that the ultimate outcome of these matters will not have a material adverse impact on the subsidiary's financial position, results of operations or cash flows.

7. Exceptional items included in the above results includes:

Particulars	(₹ in lacs)			
	Quarter ended June 30, 2013	Quarter ended March 31, 2013	Quarter ended June 30, 2012	Year ended March 31, 2013
a) Gain/ (loss) on dilution of stake in Religare Health Trust ("RHT")	(513)	(23)	(209)	99,589
b) Expense in relation to discontinuing of operations of Dental Corporation Holdings Limited ("DC")	-	-	-	(3,130)
c) Gain on dilution of stake in Dental Corporation Holdings Limited ("DC")	961	-	-	-
d) Realized foreign exchange fluctuation loss on settlement of loans within the group from sale proceeds of DC	(8,907)	-	-	-
Net exceptional items	(8,459)	(23)	(209)	96,459

Gain on dilution of stake in RHT

During year ended March 31, 2012, the Company initiated internal corporate restructuring within the Group with a view to streamline and focus Group companies' resources and energies on different divisions and undertakings and to align the business with the internationally emerging trends by moving towards innovative and cost effective methods such as transformation to asset light models. Subsequent to it RHT, a business trust established in Singapore, was listed on the Singapore Exchange Securities Trading Limited on October 19, 2012.

RHT made an offering of 567,455,000 common units at S\$ 0.90 per common unit. Post the listing of RHT on Singapore Stock Exchange on October 19, 2012, the stake of Group in RHT has been diluted from 100% to 28%. Accordingly, assets and liabilities of Clinical Establishment Division held by RHT



Group do not form part of the consolidated assets and liabilities of the Company w.e.f. October 19, 2012. Such deconsolidation had resulted in a net gain of ₹ 99,589 lacs (net of expenses directly incurred on the transaction) and has been included as an exceptional item for the year ended March 31, 2013.

8. Discontinuing of operations relating to Dental Corporation Holdings Limited ("DC"), Australia

During the previous year, Fortis Healthcare Australia Pty Limited (FHA), a wholly owned subsidiary of the Company entered into a Non-Binding Indicative offer to divest its 63.51% holding in DC to BUPA, Australia for a consideration of AUD 276 million. The deal has since been completed in the current quarter on May 31, 2013 post approvals by the shareholders of DC, other regulatory authorities and the Supreme Court of Victoria (Australia). Accordingly assets and liabilities of DC do not form part of the consolidated assets and liabilities of the Company w.e.f. May 31, 2013. Such deconsolidation has resulted in a net gain of ₹ 961 lacs and has been included as an exceptional item for the quarter ended June 30, 2013. Further, exceptional item also includes ₹ 8,907 lacs of realized foreign exchange fluctuation loss on settlement of loans within the group from sale proceeds of DC.

The revenue and expenses in respect of the activities attributable to above discontinuing operations included in the consolidated financial results are as follows:

Particulars	Quarter ended			Year ended
	30-Jun-13	31-Mar-13	30-Jun-12	31-Mar-13
Total income	33,044	49,925	40,706	180,497
Total expenditure	34,294	46,988	37,466	165,435
Profit before tax	(1,250)	2,937	3,240	15,062
Tax expenses	(70)	868	931	4,372
Profit after tax	(1,180)	2,069	2,309	10,690

(₹ In lacs)

9. Management of two subsidiaries of the group in Singapore had determined change in the company's reporting currency from Singapore dollars (SGD) to United States dollars (USD) with effect from 1 April 2012. Prior to 1 April 2012, these companies had invoiced its subsidiaries for management fees in Singapore Dollars, United States Dollars ("USD"), Australian Dollars ("AUD") and Hong Kong Dollars. With effect from 1 April 2012 onwards, invoicing for management fees is being done in United States dollars. This change in reporting currency of the group's subsidiaries has been applied prospectively.

10. During the current quarter, Fortis Healthcare International Pte Ltd., a subsidiary of the Company has entered into an agreement with Viva Holdings Vietnam (Pte.) Ltd, a Chandler Corporation company, to divest entire stake in Fortis Hoan My (Vietnam), for a consideration of USD 80 million. The deal is expected to be completed by September 2013 and is subject to regulatory approvals. Pending approvals, no effect of the proposed deal has been given in the above unaudited financial results.

11. During the current quarter, the company raised USD 55 million through issue of 550 Foreign Currency Convertible Bonds (FCCB's) of USD 100,000 each. The proceeds of the issue have been primarily used for repayment of debts.

12. During the current quarter company has allotted 18,833,700 equity shares to International Finance Corporation pursuant to preferential allotment at ₹ 99.09 per share including premium of ₹ 89.09 per share aggregating to ₹ 18,662 lacs.



13. During the current quarter, Company has successfully concluded issue of 34,993,030 equity shares of face value ₹ 10 each at a price of ₹ 92 per equity share through an Institutional Placement Programme (IPP). The total proceeds of the Issue was ₹ 32,194 lacs. As at June 30, 2013, ₹ 6,902 lacs has been utilized out of the issue proceeds.
14. Subsequent to June 30, 2013, the Company has successfully concluded issue of 150 Foreign Currency Convertible Bonds ('FCCB') of USD 200,000 each due in August 2018. FCCB will be listed on Singapore Exchange Securities Trading Limited (the 'SGX-ST').
15. As permitted by the guidance note on the Revised Schedule VI to the Companies Act, 1956, the Group has elected to present earnings before interest, tax, depreciation and amortization (EBITDA) as a separate line item in its financial statements and as required by clause 41 to the listing agreement to use the classifications as per Revised Schedule VI, the Group has shown the EBITDA as a separate line item in the above financial results. In its measurement, the Group does not include depreciation and amortization expense, finance costs and tax expense.
16. The previous periods' year figures have been regrouped and recasted, wherever considered necessary.

Date: August 8, 2013
Place: Gurgaon

anurag

for and on behalf of the Board of Directors

Malvinder Mohan Singh
Malvinder Mohan Singh
Executive Chairman



**Certified True Copy
For Fortis Healthcare Limited**

[Signature]
Company Secretary